Literature DB >> 22237726

Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.

Seiki Hasegawa1, Nobuyuki Kondo, Seiji Matsumoto, Teruhisa Takuwa, Masaki Hashimoto, Hayato Orui, Shunichi Fukuda, Kazue Yoneda, Yoshitomo Okumura, Noriaki Tsubota, Kazuya Fukuoka, Ikuko Torii, Tohru Tsujimura, Takashi Nakano.   

Abstract

Malignant pleural mesothelioma (MPM) remains suffering poor prognosis in spite of recent diagnostic and therapeutic progress. Although there is currently no established evidence, early diagnosis and early intervention may play a key role to improve prognosis of MPM, similarly to other malignancies. As pleural effusion is usually the first clinical sign of MPM, pleural effusion cytology is often the first diagnostic examination to be carried out. Since the sensitivity of pleural effusion cytology is approximately 60%, however, false-negative diagnosis is given to almost half of true MPM patients at this clinical step. One practical way to reduce the number of misdiagnosed MPM is to encourage performing thoracoscopic pleural biopsy unless definitive diagnosis other than MPM is established. There still remain a considerable number of patients with radiological/thoracoscopic T0 MPM who are misdiagnosed with nonspecific pleuritis after a complete investigation including thoracoscopic biopsies. Such patients will turn out to be malignant during follow-up period, although they have the best opportunity for long-term survival if only early therapeutic intervention is given. Currently, we are performing diagnostic total parietal pleurectomy in highly selected patients, who are characterized with strong clinical suspicion, positive pleural effusion cytology but uncertain pathological diagnosis, excellent cardiopulmonary reserve, and with written informed consent for highly invasive diagnostic surgery for pathologically unproven disease.

Entities:  

Mesh:

Year:  2012        PMID: 22237726     DOI: 10.1007/s10147-011-0368-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  71 in total

1.  Malignant pleural mesothelioma: a population-based study of survival.

Authors:  Michael T Milano; Hong Zhang
Journal:  J Thorac Oncol       Date:  2010-11       Impact factor: 15.609

2.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Authors:  Matthew Bott; Marie Brevet; Barry S Taylor; Shigeki Shimizu; Tatsuo Ito; Lu Wang; Jenette Creaney; Richard A Lake; Maureen F Zakowski; Boris Reva; Chris Sander; Robert Delsite; Simon Powell; Qin Zhou; Ronglai Shen; Adam Olshen; Valerie Rusch; Marc Ladanyi
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

Review 3.  Pathology of the pleura: what the pulmonologists need to know.

Authors:  Philip T Cagle; Timothy Craig Allen
Journal:  Respirology       Date:  2011-04       Impact factor: 6.424

4.  Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.

Authors:  Jenette Creaney; Nola J Olsen; Fraser Brims; Ian M Dick; Arthur W Musk; Nicholas H de Klerk; Steven J Skates; Bruce W S Robinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-22       Impact factor: 4.254

5.  Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.

Authors:  J Scurry; M A Duggan
Journal:  J Clin Pathol       Date:  1999-07       Impact factor: 3.411

6.  Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Authors:  Harvey I Pass; Anil Wali; Naimei Tang; Alla Ivanova; Sergey Ivanov; Michael Harbut; Michele Carbone; Jeffrey Allard
Journal:  Ann Thorac Surg       Date:  2008-01       Impact factor: 4.330

7.  Mesothelin-family proteins and diagnosis of mesothelioma.

Authors:  Bruce W S Robinson; Jenette Creaney; Richard Lake; Anna Nowak; A William Musk; Nick de Klerk; Pernilla Winzell; Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

Review 8.  Advances in the systemic therapy of malignant pleural mesothelioma.

Authors:  Dean A Fennell; Giovanni Gaudino; Kenneth J O'Byrne; Luciano Mutti; Jan van Meerbeeck
Journal:  Nat Clin Pract Oncol       Date:  2008-03

9.  Codeletion of p15 and p16 in primary malignant mesothelioma.

Authors:  S Xio; D Li; J Vijg; D J Sugarbaker; J M Corson; J A Fletcher
Journal:  Oncogene       Date:  1995-08-03       Impact factor: 9.867

10.  Germline BAP1 mutations predispose to malignant mesothelioma.

Authors:  Joseph R Testa; Mitchell Cheung; Jianming Pei; Jennifer E Below; Yinfei Tan; Eleonora Sementino; Nancy J Cox; A Umran Dogan; Harvey I Pass; Sandra Trusa; Mary Hesdorffer; Masaki Nasu; Amy Powers; Zeyana Rivera; Sabahattin Comertpay; Mika Tanji; Giovanni Gaudino; Haining Yang; Michele Carbone
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

View more
  1 in total

Review 1.  Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.

Authors:  Volker Neumann; Stefan Löseke; Dennis Nowak; Felix J F Herth; Andrea Tannapfel
Journal:  Dtsch Arztebl Int       Date:  2013-05-03       Impact factor: 5.594

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.